pranlukast

08/01/2001 - "Protocol 2: Pranlukast was effective in group I and II, but not in group III. In groups I and II, pranlukast tended to be more effective when BDP was introduced within the first year of onset of asthma. "
09/01/1999 - "Clinical studies have shown that pranlukast (Ono Pharmaceutical Co., Osaka, Japan) is effective for mild and moderate asthma. "
01/01/2004 - "Long-term treatment with pranlukast is effective for the management of bronchial asthma, particularly in patients with mild to moderate disease. "
01/01/2003 - "Pranlukast was also effective in patients with mild to severe asthma in a clinical practice setting. "
11/01/1999 - "Because of its anti-inflammatory effects, ONO-1078 should be useful in the treatment of bronchial asthma."

01/01/2012 - "These results demonstrate that pranlukast is effective for the relief of congestion due to pollinosis."
12/01/2011 - "Pranlukast is effective for prophylactic treatment of pollinosis."
01/01/2009 - "To investigate the efficacy of pranlukast as an early intervention in the control of cedar pollinosis. "
01/01/2014 - "Placebo-controlled study with OHIO chamber of prophylactic pranlukast for children with Japanese cedar pollinosis: TOPIC-J III study."
12/01/2011 - "Therefore, this study was performed to determine if pranlukast, a LTRA, met these goals in treatment of pollinosis. "

01/01/2009 - "Administering pranlukast immediately before the beginning of cedar pollen dispersion is effective in reducing symptoms of allergic rhinitis throughout the dispersion period."
07/01/2006 - "Early Pranlukast intervention could inhibit nasal mucosal remodeling in allergic rhinitis."
07/01/2006 - "To explore the impact of Pranlukast in nasal mucosal remodeling in experimental allergic rhinitis. "
07/01/2006 - "[Effect of Pranlukast on tissue remodeling in experimental guinea pig allergic rhinitis model]."
12/01/1997 - "A cysLT antagonist, pranlukast, may thus prevent cysLT-mediated symptoms of allergic rhinitis."

03/01/2006 - "Pranlukast exerts an anti-inflammatory effect on focal cerebral ischemia in the subacute phase that is limited to neutrophil recruitment through the disrupted blood-brain barrier."
03/01/2006 - "Pranlukast reduces neutrophil but not macrophage/microglial accumulation in brain after focal cerebral ischemia in mice."
02/01/2001 - "ONO-1078 showed protective effect on focal cerebral ischemia. "
03/01/2006 - "To determine whether pranlukast, a cysteinyl leukotriene receptor-1 antagonist, exerts an anti-inflammatory effect on focal cerebral ischemia in mice. "
02/01/2001 - "[Protective effect of ONO-1078, a leukotriene antagonist, on focal cerebral ischemia in mice]."

08/16/2005 - "After ischemia, pranlukast (0.1 mg/kg) was injected intraperitoneally for 5 consecutive days. "
12/01/2003 - "ONO-1078 (0.1, 0.3 mg/kg) and edaravone (10 mg/kg) improved ischemia-induced neurological deficiency and reduced neuron death. "
01/01/2018 - "After ischemia, the CysLTR antagonists Pranlukast (0.1 mg/kg) and HAMI 3379 (0.1 mg/kg) were injected intraperitoneally for 5 consecutive days in the last two groups,while the former two groups were injected with saline only (10 mL/kg). "
12/01/2003 - "ONO-1078 (0.03-0.3 mg/kg) and edaravone (MCI-186, 3-methyl-1-phenyl-2-pyrazolin-5-one, a neuroprotective agent) 10 mg/kg were ip injected 30 min before ischemia and 1 h after reperfusion, and once a day afterward. "
08/16/2005 - "These findings indicate that pranlukast has a long-lasting protective effect on focal cerebral ischemia in mice, and inhibit the ischemia-induced glial scar formation, providing further evidence of the therapeutic potential of pranlukast in the treatment of ischemic stroke."